Concerns over malfunctions in genetic testing for breast cancer in Israel
The Ministry of Health recently issued a concerning notice regarding genetic test kits used to detect mutations in the BRCA1 gene, which is linked to an increased risk of developing breast cancer. According to reports, there is a concern that some of the tests performed by the company "Gamidor" yielded false-negative results.
The malfunction was discovered following an unusual report received by the Ministry of Health. The tests in question were intended to identify a genetic predisposition to the disease, and according to the data, these tests were performed for more than 90,000 subjects during the recent period. A false-negative result could mislead patients and prevent them from receiving necessary preventive treatment or medical monitoring.
Following the exposure of the case, the Ministry of Health has begun an in-depth investigation into the matter to understand the scope of the malfunction and its causes. The healthcare system emphasizes that this is an exceptional event that requires immediate attention to ensure public health and the reliability of genetic tests performed in Israel.
As of now, the Ministry is working with the relevant parties to update the subjects who may be affected by the malfunction. Medical experts recommend that anyone who has performed the test in the past and is concerned about the results should contact their attending physician or the genetic institute where the test was performed to receive further instructions.